MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Reaffirmed by Cantor Fitzgerald

MoonLake Immunotherapeutics (NASDAQ:MLTX)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports.

Several other equities research analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a report on Thursday, September 12th. Wolfe Research lowered MoonLake Immunotherapeutics from an “outperform” rating to a “peer perform” rating in a report on Monday, August 26th. Needham & Company LLC restated a “buy” rating and issued a $62.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, September 12th. Finally, Oppenheimer initiated coverage on MoonLake Immunotherapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $104.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.45.

MoonLake Immunotherapeutics Trading Up 0.6 %

NASDAQ MLTX opened at $54.04 on Monday. MoonLake Immunotherapeutics has a 12 month low of $35.11 and a 12 month high of $64.98. The stock has a 50-day simple moving average of $46.83 and a 200 day simple moving average of $44.72. The company has a market capitalization of $3.45 billion, a PE ratio of -72.05 and a beta of 1.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.11). During the same quarter in the prior year, the company earned ($0.23) earnings per share. As a group, sell-side analysts predict that MoonLake Immunotherapeutics will post -1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Institutional investors have recently bought and sold shares of the company. Quarry LP acquired a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at approximately $51,000. Bellevue Group AG acquired a new stake in MoonLake Immunotherapeutics in the 1st quarter valued at $221,000. PNC Financial Services Group Inc. lifted its position in MoonLake Immunotherapeutics by 50.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,147 shares of the company’s stock worth $371,000 after buying an additional 2,067 shares in the last quarter. DNB Asset Management AS boosted its stake in shares of MoonLake Immunotherapeutics by 29.8% during the 2nd quarter. DNB Asset Management AS now owns 7,372 shares of the company’s stock worth $324,000 after buying an additional 1,694 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of MoonLake Immunotherapeutics in the 1st quarter valued at about $726,000. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.